secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rani Therapeutics Holdings, Inc. (RANI)
CIK:        0001856725
Form:       8-K
Filed at:   2024-05-06T23:59:59+00:00
Accession:  0000950170-24-053527
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rani Therapeutics Q1 net loss $14.8M; cash $39.6M; RT-111 Phase 1 positive
--------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities: $39.6M at March 31, 2024 (down from $48.5M year-end 2023).
- Net loss $14.8M for Q1 2024 vs $16.8M same quarter 2023; includes $3.9M stock-based comp.
- R&D expense $7.6M (down $2.1M YoY) on lower compensation and third-party costs.
- RT-111 (oral anti-IL-12/23 antibody) Phase 1 achieved high bioavailability, well-tolerated, no serious AEs.
- Expects Phase 2 trial for RT-102 (osteoporosis) in 2024; RaniPill HC Phase 1 readiness H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1856725/000095017024053527/0000950170-24-053527-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1856725/000095017024053527/rani-20240506.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-053527

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer